HomeCompareIPZYF vs MRK

IPZYF vs MRK: Dividend Comparison 2026

IPZYF yields 248.29% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPZYF wins by $441.35M in total portfolio value
10 years
IPZYF
IPZYF
● Live price
248.29%
Share price
$0.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$441.40M
Annual income
$246,281,693.35
Full IPZYF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — IPZYF vs MRK

📍 IPZYF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPZYFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPZYF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPZYF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPZYF
Annual income on $10K today (after 15% tax)
$21,104.90/yr
After 10yr DRIP, annual income (after tax)
$209,339,439.35/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, IPZYF beats the other by $209,330,842.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPZYF + MRK for your $10,000?

IPZYF: 50%MRK: 50%
100% MRK50/50100% IPZYF
Portfolio after 10yr
$220.73M
Annual income
$123,145,903.56/yr
Blended yield
55.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

IPZYF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
3.6
Piotroski
4/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPZYF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPZYFMRK
Forward yield248.29%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$441.40M$57.7K
Annual income after 10y$246,281,693.35$10,113.78
Total dividends collected$420.53M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: IPZYF vs MRK ($10,000, DRIP)

YearIPZYF PortfolioIPZYF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$35,529$24,829.30$11,213$373.04+$24.3KIPZYF
2$120,462$82,445.57$12,667$512.06+$107.8KIPZYF
3$390,138$261,244.20$14,439$708.14+$375.7KIPZYF
4$1,208,185$790,736.66$16,640$988.16+$1.19MIPZYF
5$3,581,320$2,288,562.15$19,432$1,394.07+$3.56MIPZYF
6$10,172,004$6,339,991.53$23,057$1,992.90+$10.15MIPZYF
7$27,713,431$16,829,387.07$27,889$2,894.79+$27.69MIPZYF
8$72,505,096$42,851,724.63$34,518$4,286.29+$72.47MIPZYF
9$182,356,681$104,776,228.36$43,912$6,494.35+$182.31MIPZYF
10$441,403,342$246,281,693.35$57,714$10,113.78+$441.35MIPZYF

IPZYF vs MRK: Complete Analysis 2026

IPZYFStock

IP Group Plc is a private equity and venture capital firm specializing in seed, early stage, start-up, incubation, growth capital, and mature financing. The firm also provides seed capital financing to spin out companies from the universities. It seeks to invest in the life sciences, physical sciences, energy & renewables, medical equipment and supplies, healthcare, technology, cleantech, intellectual property, pharmaceuticals & biotechnology, information technology & communications, and chemicals & materials. It also provides support for its university partners' intellectual property commercialization activities, as well as in the identification of intellectual property. It typically invests between £0.5 million ($0.75 million) and £1 million ($1.50 million) per investment. The firm prefers to takes equity positions in its portfolio companies. IP Group Plc was founded in 2001 and is based in London, United Kingdom with additional offices in Wilmington, Delaware; Hong Kong S.A.R., Hong Kong and Melbourne, Australia.

Full IPZYF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this IPZYF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPZYF vs SCHDIPZYF vs JEPIIPZYF vs OIPZYF vs KOIPZYF vs MAINIPZYF vs JNJIPZYF vs ABBVIPZYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.